World Hepatitis Day 2024

Tags:

Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study

Elsevier, The Lancet Regional Health - Western Pacific, Volume 48, July 2024

This Article supports SDG 3 by assessing the effectiveness of a hepatitis B model of care in Australia, suggesting that the model, involving primary health care, could be rolled out nationally or internationally. The authors suggest that the model could have positive implications particularly for low-income and middle-income countries.

SDG:

Tags:

Health and population, Oceania

Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study

Elsevier, eClinicalMedicine, Volume 73, July 2024

This Article supports SDG 4 by documenting significant improvements in fibrosis-based liver disease burden with direct-acting antivirals, among a cohort of patients with chronic hepatitis C.

SDG:

Tags:

Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021: Spending on NA for HBV in Medicaid 2012-2021

Elsevier, Annals of Hepatology, Volume 29, 1 July 2024

This study supports SDG 3 by analyzing expenditures on hepatitis B treatments, promoting better health resource management.

SDG:

Tags:

Screening for hepatitis B in the Bronx West African community with a blood pressure cuff: a cohort study

Elsevier, The Lancet Regional Health - Americas, Volume 35, July 2024

This Article supports SDG 3 by evaluating a hepatitis B screening programme in which members of the West African community in the Bronx were offered hepatitis B testing when they attended a blood pressure clinic visit following an educational intervention about hypertension. Almost all participants accepted to have hepatitis B screening, showing the effectiveness of its being linked to blood pressure testing.

SDG:

Tags:

Health and population, North America

Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis

Elsevier, eClinicalMedicine, Volume 72, June 2024

This Article supports SDG3 by evaluating sex and gender disparities in terms of risk factors, treatment uptake/completion, and virological outcomes for hepatitis C, finding differences between men and women in, for example, exposure to different risk factors and likelihood of commencing treatment. More attention is needed in research to these disparities and how they could be addressed

SDG:

Tags:

Network pharmacology-based analysis on the key mechanisms of Yiguanjian acting on chronic hepatitis

Elsevier, Heliyon, Volume 10, 15 May 2024

Interesting study on examining the potential molecular mechanism of YGJ using network pharmacology to investigate how Traditional Chinese Medicine disease treatment offers numerous benefits when treating chronic hepatitis.

SDG:

Tags:

Health and wellbeing; Health and population, Global

Factors associated with hepatitis B vaccination in Laos: findings from the multiple indicator cluster surveys in 2011/12 and 2017

Elsevier, The Lancet Regional Health - Western Pacific, Volume 46, May 2024

This Article supports SDG3 by investigating the barriers to receiving childhood hepatitis B vaccines in Laos. The findings suggest that socioeconomic factors play a substantial role in the variation in vaccine coverage, particularly household income and education.

SDG:

Tags:

Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study

Elsevier, The Lancet Global Health, Volume 12, May 2024

This Article supports SDG 3 by demonstrating the effectiveness of assisted partner services in Kenya to test the partners of people who inject drugs for HIV and hepatitis C, and support linkage to and engagement in care among those who are positive for either infection.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Health and population, Africa

Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!

Elsevier, American Journal of Transplantation, Volume 24, May 2024

Nearly 2.4% of global deaths in 2019 were attributed to cirrhosis, which has increased since 2017. Liver transplantation (LT) is accepted as a lifesaving therapy for patients with complications of cirrhosis or hepatocellular cancer, but there are several barriers toward equitable access. This article outlines ways to reduce the disparities

SDG:

Tags:

Science; Health and population, Global

Development of novel prognostic models based on dynamic changes in risk factors for hepatitis B associated acute-on-chronic liver failure:a 10-year retrospective study

Elsevier, Heliyon, Volume 10, 15 April 2024

This study aims to develop novel prognostic models based on the dynamic changes in variables to predict the short-term mortality of HBV-associated ACLF (HBV-ACL)

SDG:

Goal 3: Good health and well-being; Goal 12: Responsible consumption and production

Tags:

Health and wellbeing; Health and population, Global

Global outbreaks of foodborne hepatitis A: Systematic review and meta-analysis

Elsevier, Heliyon, Volume 10, 15 April 2024

Systematic review on Global outbreaks of foodborne hepatitis

SDG:

Tags:

Health and wellbeing; Food security and nutrition and sustainable agriculture; Health and population, Global

People in community corrections are a population with unmet need for viral hepatitis care

Elsevier, eClinicalMedicine, Volume 70, April 2024

This Article supports SDG 3 by arguing that people under community correction supervision (probation or parole) are a large population of individuals at risk of viral hepatitis, to whom little attention has thus far been paid. Targeting hepatitis testing and treatment services at this population would be feasible and effective in reducing hepatitis incidence.

SDG:

Tags:

Towards elimination of chronic viral hepatitis in French Polynesia: results from a national population-based survey

Elsevier, The Lancet Regional Health - Western Pacific, Volume 45, April 2024

This Article supports SDG 3 by assessing the prevalence of hepatitis B, C, and delta virus in French Polynesia. The findings suggest that the HBV vaccination policy is effective and that HCV and HDV have very low levels of transmission, although some areas did have higher HBV prevalence, warrenting improved vaccine coverage and awareness.

SDG:

Tags:

Health and population; Data & Analytics, Pacific

Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis

Elsevier, eClinicalMedicine, Volume 69, March 2024

This Article supports SDG 3 by showing that providing hepatitis C testing services in pharmacies would be beneficial in increasing case detection, in keeping with growing evidence showing the benefits of providing hepatitis services in community settings. Further research is needed to evaluate the provision of hepatitis C treatment, and hepatitis B testing and treatment, in pharmacies

SDG:

Tags:

Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study

Elsevier, Transplantation and Cellular Therapy, Volume 30, March 2024

Despite the long duration of NA therapy, multiple reactivations of HBV after NA discontinuation were common in patients with HBV reactivation.

SDG:

Tags:

Health and wellbeing; Health and population, Global

Embedding viral hepatitis into primary healthcare: results of a strategic landscape analysis in Vietnam and the Philippines

Elsevier, The Lancet Regional Health - Western Pacific, Volume 44, March 2024

This Review supports SDG 3 by describing the national response to hepatitis B and C virus in Viet Nam and the Philippines, finding that although both countries have robust policies, there are differences between them in political commitment, funding, and engagement

SDG:

Tags:

Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead

Elsevier, Acta Pharmaceutica Sinica B, Volume 14, March 2024

Liver fibrosis, caused by hepatitis and other hepatic diseases, has few treatment options and is a major cause of global mortality. This study discusses potential epigenetic options for future treatments.

SDG:

Tags:

Health and wellbeing; Health and population, Global

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

Elsevier, Pharmacological Research, Volume 200, February 2024

Drug-induced liver injury (DILI) is responsible for 10% of cases of hepatitis in adults, and 13–17% of cases of fulminant hepatitis. The article proposes a way forward and roadmap to prioritize DILI research and clinical science.

SDG:

Tags:

Health and wellbeing; Health and population, Europe

Hepatitis C virus diversity and treatment outcomes in Benin: a prospective cohort study

Elsevier, The Lancet Microbe, Volume , 2024

This Article supports SDG 3 sequencing hepatitis C virus genomes in west Africa, showing the level of genotypic diversity and measuring the response to direct-acting antivirals.

SDG:

Tags:

Health and population, Africa

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Elsevier, The Lancet Regional Health - Europe, Volume 36, January 2024

This Article supports SDG 3 by estimating the prevalence of chronic hepatitis C virus infection in Europe and suggesting that EU countries need to scale up testing and treatment linkage, as well as review overall strategies for hepatitis prevention.

SDG:

Tags:

Health and population; Data & Analytics, Europe

Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study

Elsevier, The Lancet Regional Health - Americas, Volume 29, January 2024

This Article supports SDG 3 by showing that mobile health clinics can be a feasible and effective way of providing hepatitis C services to underserved, at-risk populations who face barriers to care. Policymakers should consider implementing such programmes in order to increase diagnosis and treatment rates and improve outcomes among these populations.

SDG:

Tags:

Health and population, North America

Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western Croatia

Elsevier, Annals of Hepatology, Volume 29, 1 January 2024

This study supports SDG 3 by providing data on the prevalence and characteristics of occult hepatitis B virus infection.

SDG:

Tags:

Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis

Elsevier, eClinicalMedicine, Volume 66, December 2023

This Article supports SDG 3 by showing that there is a high global seroprevalence of HCV infection among pregnant women (estimated at 2.2–5.3 million cases worldwide), and particularly in lower-income settings. The authors suggest policy implications, such as expanding screening programmes for pregnant women and women of childbearing age, particularly in lower-income settings.

SDG:

Tags:

Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review

Elsevier, The Lancet Global Health, Volume 11, December 2023

This Article supports SDG 3 by providing estimates of HIV and hepatitis C testing and treatment uptake among people who inject drugs. Data availability was variable, and where data were available, uptake was generally suboptimal, indicating a need for countries to implement targeted interventions to improved testing, linkage to care, and treatment among people who inject drugs

SDG:

Tags:

Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe

Elsevier, The Lancet Regional Health - Europe, Volume 34, November 2023

This Series paper supports SDG 3 by evaluating existing and emerging vaccines and vaccination campaigns against hepatitis B virus and other sexually transmitted infections, as well as other interventions such as PrEP for HIV

SDG:

Tags:

Health and population, Europe

Hepatitis C and hepatocellular carcinoma in Latin America: Elimination as a path to cancer prevention

Elsevier, Annals of Hepatology, Volume 28, 1 November 2023

This article supports SDG 3 by highlighting the importance of hepatitis C elimination to prevent liver cancer in Latin America.

SDG:

Tags:

Develop and validate a novel online AIHI-nomogram to predict severe liver inflammation in patients with autoimmune hepatitis

Elsevier, Annals of Hepatology, Volume 28, 1 November 2023

This article contributes to SDG 3 by developing predictive tools to improve clinical management of autoimmune hepatitis.

SDG:

Tags:

Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019

Elsevier, The Lancet Public Health, Volume 8, September 2023

This Article supports SDG 3 by showing that there is a high burden of hepatitis B and C infection and related liver diseases in Europe, suggesting the need for increased investment in prevention, detection, and treatment strategies is needed to bring Europe closer to the goal of elimination by 2030.

SDG:

Tags:

Health and population, Europe

Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

Elsevier, The Lancet Microbe, Volume 4, August 2023

This Article supports SDG 3 by showing that international transmission of hepatitis C virus has occurred in recent years among men who have sex with men. This suggests that international coordination will be needed for microelimination in this population.

SDG:

Tags:

A community-based strategy to eliminate hepatitis C among people who inject drugs in Vietnam

Elsevier, The Lancet Regional Health - Western Pacific, Volume 37, August 2023

Background: Towards hepatitis C elimination among people who inject drugs (PWID), we assessed the effectiveness of a strategy consisting of a community-based respondent-driven sampling (RDS) as wide screening, a simplified and integrated hospital-based care, and prevention of reinfection supported by community-based organisations (CBO), in Hai Phong, Vietnam. Methods: Adults who injected heroin were enrolled in a RDS survey implemented in two CBO premises. Rapid HIV and HCV tests were done on site, and blood was taken for HCV RNA testing.

SDG:

Tags:

Health and wellbeing, Asia

Progress towards triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Pacific Island Countries and Territories: a systematic review

Elsevier, The Lancet Regional Health - Western Pacific, Volume 35, June 2023

This Review supports SDG 3 by assessing the availablility of data for reporting elimination targets of mother-to-child transmission of HIV, hepatitis B, and syphilis, and reports on progress towards these targets in Pacific Island countries and territories.

SDG:

Tags:

Health and population; Data & Analytics, Pacific

Structural insights into hepatitis C virus neutralization

Elsevier, Current Opinion in Virology, Volume 60, June 2023

This review supports SDG 3 as despite available antiviral therapy, hepatitis C virus (HCV) remains a global health burden and a prophylactic vaccine would help to eliminate the risk to develop chronic liver diseases. This paper uses data to draw a simplified model of virus entry, which highlights gaps in our current knowledge that warrant further research to fully understand this process at the atomic level.

SDG:

Tags:

Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide

Elsevier, The Lancet Regional Health - Western Pacific, Volume 35, June 2023

This Article supports SDG 3 by evaluating shared-care models with hepatitis B virus testing in China, including an analysis of the cost-effectiveness and the impact on quality of life and mortality.

SDG:

Tags:

Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation

Elsevier, The Lancet Regional Health - Western Pacific, Volume 35, June 2023

This Article supports SDG 3 by evaluating alanine transaminase antiviral treatments for hepatitis B virus infection in China. The authors suggest the optimal treatment coverage for both cost-effectiveness and mortality reduction based on their findings

SDG:

Tags:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Hepatitis C mortality trends in Mexico from 2001 to 2017

Elsevier, Annals of Hepatology, Volume 28, 1 May 2023

Introduction and Objectives: We aimed to analyze the trends of total and sex-stratified mortality from hepatitis C virus (HCV) and to estimate the proportion of non-alcoholic liver disease deaths in Mexico attributable to HCV from 2001-2017. Materials and Methods: Using the mortality multiple-cause dataset, we selected the codes for acute HCV and chronic HCV to analyze trends from 2001 to 2017.

SDG:

Tags:

Health and wellbeing, South America

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance: Effectiveness of elbasvir/grazoprevir in HCV

Elsevier, Annals of Hepatology, Volume 28, 1 March 2023

Introduction and Objectives: In clinical trials, patients with hepatitis C virus (HCV) genotype (GT)1a infection and baseline resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 receiving elbasvir/grazoprevir for 12 weeks achieved lower rates of sustained virologic response (SVR) than those without baseline RASs. SVR rates in patients with RASs were improved when elbasvir/grazoprevir treatment duration was extended from 12 to 16 weeks and administered concomitantly with ribavirin.

SDG:

Goal 3: Good health and well-being; Goal 10: Reduced inequalities

Tags:

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial

Elsevier, Vaccine, Volume 41, 27 January 2023

This Article supports SDG 3 as the results show that two doses of the HEV 239 vaccine produces broad and likely functional immune responses against HEV that remain for at least two years. The safety profile was acceptable and a phase four study of HEV 239 in rural Bangladesh is feasible.

SDG:

Tags:

Clinical study on the efficacy of hepatitis B vaccination in hepatitis C virus related chronic liver diseases in Egypt

Elsevier, Virus Research, Volume 323, 2 January 2023

This article supports SDG 3 as chronic hepatitis B (HBV) and C virus (HCV) infections represent significant public health issues internationally. This paper aims to evaluate the efficacy of hepatitis B vaccination in HCV-related chronic liver disease and identify possible factors that may contribute to hypo-responsiveness in those patients.

SDG:

Tags:

Hepatitis D virus: Improving virological knowledge to develop new treatments

Elsevier, Antiviral Research, Volume 209, January 2023

This review supports SDG3 by detailing the current fundamental knowledge of HDV lifecycle and review antiviral treatments under development against this virus, outlining their respective mechanisms-of-action. Finally, it describes the antiviral effect these compounds are showing in ongoing clinical trials, discussing their promise and potential pitfalls for managing HDV infected patients.

SDG:

Tags:

De novo modelling of HEV replication polyprotein: Five-domain breakdown and involvement of flexibility in functional regulation

Elsevier, Virology, Volume 578, January 2023

This article supports SDG 3 by providing accurate folds of Hepatitis E Virus' five domains. The work highlights that there is no canonical protease encoded in pORF1 and that flexibility in several functionally important regions rather than proteolytic processing may serve to regulate HEV RNA synthesis

SDG:

Tags:

Vitamin D role in hepatitis B: focus on immune system and genetics mechanism

Elsevier, Heliyon, Volume 8, November 2022

According to the World Health Organization (WHO) report, viral hepatitis has been a problem in human society. Vitamins play a significant role in preventing the hepatocarcinoma and liver cirrhosis. In this report, we will first focus on the vitamin D function in the immune system reactions, and then investigate its role in the viral infections and the signaling pathway of hepatitis B virus. The existence of the cytochrome P450 (CYP) 27B1 enzyme, which is involved in vitamin D synthesis in immune system cells, has drawn researchers ' attention to the field of immune system.

SDG:

Tags:

Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity

Elsevier, Heliyon, Volume 7, June 2021

Background: Viral hepatitis could have an impact on the treatment response in HIV patients. In this study, we sought to determine the prevalence of hepatitis B and C infections and examine the effect on the treatment response in HIV-1 patients attending antiretroviral therapy (ART) centers in the Volta and Oti Regions of Ghana. Method: A longitudinal study design was employed.

SDG:

Tags:

Health and wellbeing, Africa

A novel hepatitis B virus recombinant genotype D4/E identified in a South African population

Elsevier, Heliyon, Volume 5, April 2019

Background: Genetic diversity is a characteristic trait of the hepatitis B virus (HBV) and has been associated with different clinical outcomes. In South Africa, HBV infection is a major public health concern. Most HBV infections are caused by genotype A strains. However rare cases of infection with HBV genotype D have been reported. The purpose of this study was to investigate the molecular characteristics of a rare HBV subgenotype D4 isolate. Methods: The full-length genome of isolate ZADGM6964 was amplified in a one-step polymerase chain reaction.

SDG:

Tags:

Health and wellbeing, Africa

Development and validation of a noninvasive prediction model for significant hepatic liver fibrosis in Chinese patients with autoimmune hepatitis

Elsevier, Annals of Hepatology, Volume 29, 1 May 2024

This article supports SDG 3 by developing noninvasive tools for predicting liver fibrosis in autoimmune hepatitis patients.

SDG:

Tags:

MiR-326 sponges TET2 triggering imbalance of Th17/Treg differentiation to exacerbate pyroptosis of hepatocytes in concanavalin A-induced autoimmune hepatitis

Elsevier, Annals of Hepatology, Volume 29, 1 March 2024

This study supports SDG 3 by providing insights into the mechanisms of autoimmune hepatitis and potential therapeutic targets.

SDG:

Tags:

The landscape of inpatient admissions for alcoholic hepatitis in the era of early liver transplantation

Elsevier, Annals of Hepatology, Volume 29, 1 March 2024

This study supports SDG 3 by examining the impact of early liver transplantation on hospital admissions for alcoholic hepatitis.

SDG:

Tags:

NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study

Elsevier, Annals of Hepatology, Volume 29, 1 January 2024

This study supports SDG 3 by investigating the relationship between NAFLD and liver fibrosis in chronic hepatitis B patients.

SDG:

Tags:

A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues

Elsevier, Annals of Hepatology, Volume 29, 1 January 2024

This study supports SDG 3 by developing predictive tools for treatment outcomes in chronic hepatitis B patients.

SDG:

Tags:

Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysis

Elsevier, Annals of Hepatology, Volume 29, 1 January 2024

This article supports SDG 3 by providing global prevalence data on occult HBV infection in younger populations.

SDG:

Tags:

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

Elsevier, Annals of Hepatology, Volume 28, 1 September 2023

This study contributes to SDG 3 by addressing safety improvements in hepatitis B treatment regimens.

SDG:

Tags:

IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico

Elsevier, Annals of Hepatology, Volume 28, 1 September 2023

This article supports SDG 3 by improving diagnostic capabilities for hepatitis E virus in blood donors.

SDG:

Tags:

Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study

Elsevier, Annals of Hepatology, Volume 28, 1 July 2023

Introduction and Objectives: We initiated this multicenter study to integrate important risk factors to create a nomogram for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) for clinician decision-making. Patients and Methods: Between April 2011 and March 2022, 2281 HCC patients with an HBV-related diagnosis were included. All patients were randomly divided into two groups in a ratio of 7:3 (training cohort, n = 1597; validation cohort, n = 684). The nomogram was built in the training cohort via Cox regression model and validated in the validation cohort.

SDG:

Tags:

Early living donor liver transplantation for alcohol-associated hepatitis

Elsevier, Annals of Hepatology, Volume 28, 1 July 2023

This article supports SDG 3 by evaluating the outcomes of early liver transplantation for alcohol-associated hepatitis.

SDG:

Tags:

Good prognosis of adult hemophagocytic lymphohistiocytosis associated with the germline HAVCR2 mutation

Elsevier, Experimental Hematology, Volume 125-126, September 2023

Hepatitis A virus-cellular receptor 2 (HAVCR2) mutation can be detected in hemophagocytic lymphohistiocytosis (HLH), which is associated with good prognosis.

SDG:

Tags:

The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis

Elsevier, Heliyon, Volume 10, April 2024, e28653

This study investigated antiviral effects in a real-world cohort of non-cirrhotic CHB patients with varying degrees of HS, assessed by transient elastography (TE) with controlled attenuation parameter (CAP).

SDG:

Tags:

Health and wellbeing; Health and population, Global

Purification of hepatitis C virus core protein in non-denaturing condition

Elsevier, Journal of Virological Methods, Volume 323, January 2024, 114852

This article supports SDG 3 as understanding the role of HCV core proteins in viral diseases is crucial to elucidating disease mechanisms and identifying potential drug targets. However, purification challenges may hinder the comprehensive elucidation of the structure and biochemical properties of HCV core proteins.

SDG:

Global

Molecular Medical Microbiology, 3rd Edition - Chapter 113: Viral hepatitis A and E

Elsevier, Molecular Medical Microbiology (Third Edition), 2024, Pages 2311-2319

This content aligns with Goal 3: Good Health by providing a better understanding of the fundamental biology of the hepatitis viruses and their pathogenesis that may provide new clues to improve the prevention and treatments for these human pathogens.

SDG:

Tags:

Diagnostic Molecular Pathology, 2nd Edition - Chapter 6: Molecular testing in hepatitis virus-related disease

Elsevier, Diagnostic Molecular Pathology (Second Edition): A Guide to Applied Molecular Testing, 2024, Pages 63-77

This content aligns with Goal 3: Good Health by summarizing the current molecular methods of detection and quantification of hepatitis virus genomes, with special emphasis on the assays commercially available and applicable for clinical use.

SDG:

Tags:

Manson's Tropical Diseases, 24th Edition - Chapter 18: Viral Hepatitis

Elsevier, Manson's Tropical Diseases (Twentyfourth Edition), 2024, Pages 152-166

This content aligns with Goal 3: Good Health proving that viral hepatitis is increasing as a global challenge, in contrast to other major infectious causes of death (e.g. tuberculosis (TB), HIV, and malaria).

SDG:

Tags:

Comprehensive Guide to Hepatitis Advances - Chapter 26: Hepatitis during childhood

Elsevier, Comprehensive Guide to Hepatitis Advances, 2023, Pages 603-628

This content aligns with Goal 3: Good Health. Infectious hepatitis during childhood is classified both for clinical and academic purposes as acute or chronic, the latter carrying the highest burden of morbidity and mortality.

SDG:

Tags:

MacSween's Pathology of the Liver, 8th Edition - Chapter 8: Autoimmune Hepatitis

Elsevier, MacSween's Pathology of the Liver (Eighth Edition), 2024, Pages 527-555

This content aligns with Goal 3: Good Health and summarizes and highlights the principles of therapy for AIH of importance to pathologists.

SDG:

Tags:

Infection and Autoimmunity, 3rd Edition - Chapter 18: Vasculitides and Hepatitis C Infection

Elsevier, Infection and Autoimmunity (Third Edition), 2024, Pages 317-335

This content aligns with Goal 3: Good Health by describing cronic infection due to hepatitis C virus (HCV) that is among the most common etiologic factors of vasculitis in humans.

SDG:

Tags:

Oncogenic Viruses - Chapter 8: Strategies for the development of hepatitis B virus vaccines

Elsevier, Oncogenic Viruses, Volume 2: Medical Applications of Viral Oncology Research, 2023, Pages 173-189

This content aligns with Goal 3: Good Health. Hepatitis B remains a worrying health problem for several countries. Although vaccination has clearly been shown to be very effective in the prevention and control of the disease globally, the emergence of mutant resistant liver infections is of concern. Thus the development of new common vaccines for the prevention of all types of hepatitis is warranted.

SDG:

Tags:

Cardio-Hepatology - Chapter 9: Passive liver congestion and hypoxic hepatitis

Elsevier, Cardio-Hepatology: Connections Between Hepatic and Cardiovascular Disease, 2023, Pages 123-132

This content aligns with Goal 3: Good Health. Passive hepatic congestion is an often overlooked consequence of right heart failure.

SDG:

Tags:

Clinical Immunology, 6th Edition - Chapter 76: Inflammatory Hepatobiliary Diseases

Elsevier, Clinical Immunology (Sixth Edition): Principles and Practice, 2023, Pages 972-982

This content aligns with Goal 3: Good Health, this chapter aims at elucidating the main characteristics of AIH, PBC, and PSC, with particular interest for the clinical manifestations, pathogenesis, autoantibodies, and therapeutic options.

SDG:

Tags:

Advanced Vaccination Technologies for Infectious and Chronic Diseases - Chapter 4: Subunit protein-based vaccines

Elsevier, Advanced Vaccination Technologies for Infectious and Chronic Diseases: A Guide to Vaccinology, Developments in Immunology, 2024, Pages 51-62

This content aligns with Goal 3: Good Health. Presents the successful influenza vaccines (using hemagglutinin and neuraminidase proteins), hepatitis B surface antigen vaccine, and the human papillomavirus vaccines targeting viral capsid proteins.

SDG:

Tags:

Viral, Parasitic, Bacterial, and Fungal Infections - Chapter 59: Role of natural products in infectious diseases

Elsevier, Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies, 2023, Pages 757-770

This content aligns with Goal 3: Good Health. As per World Health Organization (WHO) recommendations, it is required to implement the evaluation studies of ethnomedicines for HIV/AIDS, malaria, tuberculosis, and other infectious treatments, to find effective and economical therapeutic agents.

SDG:

Tags:

Viral, Parasitic, Bacterial, and Fungal Infections - Chapter 8: Infections in liver transplantation

Elsevier, Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies, 2023, Pages 87-99

This content aligns with Goal 3: Good Health. Provides a firm understanding of the undulating interplay between liver graft function and a patient’s risk for infection.

SDG:

Tags:

Decision Making in Gastroenterology - Chapter 39: Alcoholic Hepatitis

Elsevier, Decision Making in Gastroenterology, 2025, Pages 80-81

This content aligns with Goal 3: Good Health. WHO helps to fight addictions to prevent chronic diseases.

SDG:

Tags:

Treatment and Management of Tropical Liver Disease - Chapter 3: Hepatitis C infection

Elsevier, Treatment and Management of Tropical Liver Disease, 2025, Pages 17-23

This content aligns with Goal 3: Good Health. Hepatitis C is a common cause of chronic hepatitis associated with a significant global burden.

SDG:

Tags:

Regulatory T Cells and Autoimmune Diseases - Chapter 19: Role of regulatory T cells in the pathogenesis and therapeutics of autoimmune hepatitis

Elsevier, Regulatory T Cells and Autoimmune Diseases, 2024, Pages 407-432

This content aligns with Goal 3: Good Health provides understanding the mechanisms involved in AIH pathogenesis controlling hepatitic inflammation.

SDG:

Tags:

Atlas of Liver Pathology, 4th Edition - Chapter 3: Viral Hepatitis

Elsevier, Atlas of Liver Pathology (Fourth Edition), 2024, Pages 29-73.e7

This content aligns with Goal 3: Good Health by providing insight into the different manifestations of hepatitis.

SDG:

Tags:

Bioreactor Design Concepts for Viral Vaccine Production - Chapter 16: Bioreactor for hepatitis C virus vaccine

Elsevier, Bioreactor Design Concepts for Viral Vaccine Production: Progress in Biochemistry and Biotechnology, 2024, Pages 297-310

This content aligns with Goal 3: Good Health The chapter provides information on a cost-effective and easy way to produce the vaccine grade HCV.

SDG:

Tags:

Principles and Practice of Pediatric Infectious Diseases, 6th Edition - Chapter 213: Hepatitis B and Hepatitis D Viruses

Elsevier, Principles and Practice of Pediatric Infectious Diseases (Sixth Edition), 2023, Pages 1125-1133.e4

This content aligns with Goal 3: Good Health. Hepatitis B prevalence is highest in the WHO Western Pacific Region and the WHO African Region, where 6.2% and 6.1% of the adult population is infected, respectively. In the WHO Eastern Mediterranean Region, the WHO South-East Asia Region, and the WHO European Region, an estimated 3.3%, 2.0%, and 1.6% of the general population is infected, respectively. In the WHO Region of the Americas, 0.7% of the population is infected. Global differences of HBsAg positivity prevalence between males (3.9%) and females (3.5%) are small.

SDG:

Tags:

Plotkin's Vaccines, 8th Edition - Chapter 29: Hepatitis E Vaccines

Elsevier, Plotkin's Vaccines (Eighth Edition), 2023, Pages 443-450.e4

This content aligns with Goal 3: Good Health. Although HEV 239 vaccine was licenced for use in China in 2011, several steps including prequalification by the World Health Organization are needed to make the vaccine available where it is most needed, in particular for use in large outbreaks in developing countries.

SDG:

Tags:

Nelson Pediatric Symptom-Based Diagnosis: Common Diseases and their Mimics, 2nd Edition - Chapter 17: Hepatomegaly

Elsevier, Nelson Pediatric Symptom-Based Diagnosis: Common Diseases and their Mimics (Second Edition), 2023, Pages 306-319.e1

This content aligns with Goal 3: Good Health. This chapter identifies potentially life-threatening conditions, to focus on emergency measures to manage immediate threats to life, and to prevent irreversible end-organ damage.

SDG:

Tags:

Ciottone's Disaster Medicine, 3rd Edition - Chapter 59: Infectious Disease in a Disaster Zone

Elsevier, Ciottone's Disaster Medicine (Third Edition), 2024, Pages 388-392

This content aligns with Goal 3: Good Health. The purpose of this chapter is to provide a background understanding and framework to aid in the prevention, identification, and control of infectious diseases in disaster zones.

SDG:

Tags:

Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant, 9th Edition - Chapter 27: Hepatitis

Elsevier, Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant (Ninth Edition), 2025, Pages 728-744.e4

This content aligns with Goal 3: Good Health. Public health programs at the governmental level are in need for prevention of the maternal-fetal transmission of these viruses and access to available antiviral therapies.

SDG:

Tags:

Metabolic Steatotic Liver Disease - Chapter 16: Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management

Elsevier, Metabolic Steatotic Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions, 2024, Pages 261-275

This content aligns with Goal 3: Good Health as this chapter will review the aspects of combined viral hepatitis and FLD, including prevalence, risk factors, natural history, pathogenesis, and management to help inform the reader of the complexity of these liver diseases.

SDG: